FDA grants priority review to Insmed's ARIKAYCE for MAC lung disease

FDA accepted Insmed's supplemental New Drug Application (sNDA) for ARIKAYCE in MAC lung disease as part of combination therapy, granting Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is set for Jan. 28, 2027. The filing seeks full approval, supported by Phase 3b ENCORE results.